Amendments to the Claims

The following listing of claims replaces all prior listings and versions of claims in this application.

1. (Original) A clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemaglutinin-neuraminidase (HN) gene.

2. (Currently amended) A pharmaceutical composition for the treatment of cancer ~~comprising as an active ingredient~~ consisting essentially of a replication-deficient lentogenic oncolytic strain of Newcastle Disease Virus (NDV) optionally in combination with a suitable carrier.

3. (Currently amended) The pharmaceutical composition according to claim 2 ~~further comprising a suitable~~ wherein the carrier is present.

4. (Currently amended) The composition according to claim 2 wherein the lentogenic strain of NDV is the HUJ strain ~~comprising~~ having the nucleotide sequence of SEQ ID NO: 1.

5. (Currently amended) The composition according to claim 4 ~~comprising~~ wherein the strain is present in an amount of $10^6 - 10^{12}$ EID_{50} per unit dose.

6. (Withdrawn, currently amended) The composition according to claim 2 ~~further comprising~~ in combination with at least one isolated viral glycoprotein having oncolytic activity.

7. (Withdrawn) The composition according to claim 6 wherein the at least one viral glycoprotein is from NDV.

8. (Withdrawn) The composition according to claim 7 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.

9. (Withdrawn) The composition according to claim 7 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.

10. (Withdrawn, currently amended) The composition according to claim 7 ~~further comprising~~ in combination with the F glycoprotein and hemaglutinin-neuraminidase (HN) glycoprotein of NDV.

11. (Withdrawn) The composition according to claim 7 wherein the viral glycoprotein is from a velogenic strain of NDV.

12. (Withdrawn) The composition according to claim 7 wherein the viral glycoprotein is from a mesogenic strain of NDV.

13. (Withdrawn) The composition according to claim 7 wherein the viral glycoprotein is from a lentogenic strain of NDV.

14. (Withdrawn, previously presented) The composition according to claim 13 wherein the lentogenic strain of NDV is the HUJ strain comprising the nucleotide sequence of SEQ ID NO: 1.

Claims 15-23. (Cancelled)

24. (Original) A method for treating cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.

25. (Original) The method of claim 24 wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection, including intradermal, intrathecal, intracisternal, and intralesional injection.

26. (Previously presented) The method of claim 24 wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.

27. (Cancelled)

28. (Currently amended) The method of claim [[27]] 24 wherein the lentogenic oncolytic strain of NDV is the HUJ strain comprising the nucleotide sequence of SEQ ID NO: 1.

29. (Currently amended) The method of claim 28 wherein the strain is present in the composition in an amount of ~~comprises~~ $10^6 - 10^{12}$ EID_{50} per unit dose.

30. (Previously presented) The method of claim 28 wherein the step of administering comprises administering the HUJ strain of NDV in a range of 20 EID_{50}/cell to 2000 EID_{50}/cell.

Claims 31-45. (Cancelled)

46. (Currently amended) A method for treating cancer in a patient comprising administering to the patient in need thereof at least one isolated polynucleotide of ~~a replication-deficient~~ the clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) according to claim 1, the at least one isolated polynucleotide encoding at least one polypeptide of NDV ~~an analog or subunit thereof~~ having oncolytic activity.

47. (Previously presented) The method of claim 46, wherein the at least one isolated polynucleotide encodes the fusion glycoprotein of Newcastle Disease Virus.

48. (Previously presented) The method of claim 46, wherein the at least one isolated polynucleotide encodes the hemaglutinin-neuraminidase glycoprotein of Newcastle Disease Virus.

49. (Previously presented) The method of claim 46, wherein a combination of polynucleotides is administered to the patient, wherein the combination includes an isolated polynucleotide encoding the fusion glycoprotein of Newcastle Disease Virus (NDV) and an isolated polynucleotide encoding the hemaglutinin-neuraminidase glycoprotein of NDV.

50. (Currently amended) The method of claim 46, which comprises administering to the patient at least one vector that comprises the at least one isolated polynucleotide of ~~a replication-deficient~~ the clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV), the at least one isolated polynucleotide encoding at least one polypeptide of NDV ~~or an analog or subunit thereof~~ having oncolytic activity.

51. (Previously presented) The method of claim 50, wherein the vector is a viral vector.

52. (Previously presented) The method of claim 50, wherein the vector is an expression vector.

Claims 53-54. (Cancelled)

55. (Withdrawn, Currently amended) A method of making ~~a cancer treatment~~ the pharmaceutical composition according to claim 2, which comprises incorporating in the composition at least one isolated polynucleotide of a replication-deficient Newcastle Disease Virus (NDV), the at least one isolated polynucleotide encoding at least one polypeptide of NDV ~~or a subunit or analog thereof~~ having oncolytic activity.

56. (Withdrawn) The method according to claim 55 which further comprises incorporating at least one isolated viral glycoprotein having oncolytic activity in the composition.

57. (Withdrawn, Currently amended) The method according to claim 46 wherein the polynucleotide ~~encoding at least one viral polypeptide, analog or subunit thereof~~ is administered with at least one isolated viral glycoprotein having oncolytic activity.

58. (Withdrawn) The method according to claim 57 wherein the at least one viral glycoprotein is from NDV.

59. (Withdrawn) The method according to claim 58 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.

60. (Withdrawn) The method according to claim 58 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.

61. (Withdrawn, Currently amended) The method according to claim [[58]] 55, which further comprises incorporating ~~further comprising~~ the F glycoprotein and hemaglutinin-neuraminidase (HN) glycoprotein of NDV in the composition prior to administration.

62. (Withdrawn) The method according to claim 58 wherein the viral glycoprotein is from a velogenic strain of NDV.

63. (Withdrawn) The method according to claim 58 wherein the viral glycoprotein is from a mesogenic strain of NDV.

64. (Withdrawn) The method according to claim 58 wherein the viral glycoprotein is from a lentogenic strain of NDV.

65. (Withdrawn, previously presented) The method according to claim 64 wherein the lentogenic strain of NDV is the HUJ strain comprising the nucleotide sequence of SEQ ID NO: 1.